Team


Cornelia Beier - CEO & Co-Founder

c.beier@lifesciences2030.com

Cornelia Beier is a health entrepreneur and a founder of several companies. Over the last 9 years she was the CEO and partner of leon-nanodrugs and is joining the supervisory board since closing a series A funding in 2015. She has 25 years of experiences in pharmaceutical and biotech industries (BMS, Takeda, Pharmacia etc.) and is focused on business development strategies, marketing, consulting, human resources and controlling in life sciences and healthcare. She was a co-founder of Oncology World, Munich, and Partner and CEO of Kohtes Klewes Healthcare (today Ketchum PLEON-Group – BBDO), Munich and Düsseldorf. 

Beside these strategic and financial driven functions Cornelia is extremely curious about human potential, healthy attitudes and the deeper meaning of human patterns regarding well-being and health. As a medical journalist she is writing in her own blog about health trends and change approaches.


Prof. Lukas A. Huber - Partner & Co-Founder

l.huber@lifesciences2030.com

Lukas A. Huber is an Austrian physician, cell biologist and university professor at the Medical University of Innsbruck. He is Scientific Director of the Austrian Drug Screening Institute (ADSI) and the Oncotyrol Center for Personalized Cancer Medicine. His main areas of focus in national and international large-scale and collaborative projects are proteomics, molecular and cell biological cancer research as well as translational oncology and drug screening.

Due to his medical background and international collaborations he was able to make important research contributions to the field of cancer as well as orphan genetic diseases. Several targets identified and validated by Huber are now in focus of pharmaceutical industry for the development of innovative inhibitors. In the competence center for personalized cancer therapy, Oncotyrol, he presently develops a new lead candidate for the treatment of Multiple Myeloma and within the private public partnership institute ADSI he is screening natural substances for the treatment of metabolic disorders.

https://scholar.google.at/citations?user=UbaAcfIAAAAJ&hl=de

https://de.wikipedia.org/wiki/Lukas_Huber_(Mediziner)

 





Our Advisor & Partner Network

Prof. Dr. Elke Günther

AIT Austrian Institute of Technology

Vienna

Christian Daimer

Stoneriver Advisors

Vienna

 

Hans-Martin Schneider

4C GROUP

Munich

Thomas Strassner

Dentons

Munich

Mag. Thomas Jungreithmeir

TJP Group/Oaklins Austria

Vienna

Robert Nachbargauer

Director of Finance & Partner

Wictory.com

Vienna

Dr. Andreas Hable

Binder Grösswang

Vienna

Gregor Wick

Advisor | Pharma & Finance

Vienna

Klaus Müller

Founder & CEO 

Wictory.com

Vienna

Dr. Christof Böhler

Böhler Life Science Advice

Switzerland

Prof. Dr. Paul Speiser

Medical University Vienna | Dept. Gynaecologic Oncology

Bernhard Hofer

Cemit

Innsbruck

Dr. Klaus Fischer

Finom Management

Vienna | St. Lambrecht

Dr. Michael Götz

Galenus Capital

Vienna

Prof. Dr. Konrad Kohler

Wissenschaftlicher Beirat -

Donau-Universität Krems

Maximilian Speiser

Managing Partner Ovartec

Vienna

Christian Sendlinger

Steuerberater EGGER DONIG-DREHER SENDLINGER

Munich


LifeSciences2030 is a group of independent scientists, entrepreneurs and investment advisors.

 

"We believe in people with ideas for the future of health!"


Our Partner Network